UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 2018
RESHAPE LIFESCIENCES INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
1-33818 |
|
48-1293684 |
(State or other jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer Identification |
1001 Calle Amanecer |
|
92673 |
(Address of principal executive offices) |
|
(Zip Code) |
(949) 429-6680
(Registrants telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07 Submission of Matters to a Vote of Security Holders
ReShape Lifesciences Inc. (the Company) held a special meeting of its stockholders on October 30, 2018. At the special meeting, the Companys stockholders approved each of the following proposals set forth in the Companys Definitive Proxy Statement on Schedule 14A, which was filed with Securities and Exchange Commission and mailed to the Companys stockholders on or about October 5, 2018.
Proposal 1:
The Companys stockholders approved a proposal to authorize the Companys Board of Directors to amend the Companys Sixth Amended and Restated Certificate of Incorporation, as amended, to effect a reverse split of the Companys issued and outstanding shares of common stock at a ratio of between 1-for-20 and 1-for-140, as set forth below.
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
|
40,201,771 |
|
18,446,661 |
|
18,487 |
|
0 |
|
Proposal 2:
The Companys stockholders approved one or more adjournments of the special meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there were insufficient votes to approve any of the proposals at the time of the special meeting or in the absence of a quorum, as set forth below.
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
|
39,785,245 |
|
17,711,887 |
|
1,169,787 |
|
0 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
RESHAPE LIFESCIENCES INC. | |
|
|
|
|
|
|
|
By: |
/s/ Scott P. Youngstrom |
|
|
Scott P. Youngstrom |
|
|
Chief Financial Officer |
|
| |
Dated: November 5, 2018 |
|